Cosmo Pharmaceuticals NV (C43) Stock Price & News

All values in EUR	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	26.23M	26.23M	25.12M	25.12M
Cost of goods sold	14.02M	14.02M	13.95M	13.95M
Cost of revenue	14.02M	14.02M	13.95M	13.95M
Research and development expenses	8.09M	8.09M	7.57M	7.57M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	6.27M	6.27M	8.32M	8.32M
Operating expense	14.97M	14.97M	14.47M	14.47M
Total operating expenses	28.99M	28.99M	28.42M	28.42M
Operating income	-2.76M	-2.76M	-3.30M	-3.30M
Other non operating income	-13.00K	-13.00K	1.61M	1.61M
EBT including unusual items	-124.00K	-124.00K	-1.89M	-1.89M
EBT excluding unusual items	-916.00K	-916.00K	-1.89M	-1.89M
Income tax expense	606.00K	606.00K	471.50K	471.50K
Effective tax rate	-488.71%	-488.71%	-24.89%	-24.89%
Other operating expenses	611.00K	611.00K	-1.42M	-1.42M
Net income	-801.00K	-801.00K	-2.38M	-2.38M
Net profit margin	-3.05%	-3.05%	-9.46%	-9.46%
Earnings per share	-	-	-	-
Interest and investment income	2.02M	2.02M	-	-
Interest expense	-28.50K	-28.50K	-202.00K	-202.00K
Net interest expenses	1.99M	1.99M	-202.00K	-202.00K
Depreciation and amortization charges	-	-	-	-
EBITDA	104.50K	104.50K	-2.50K	-2.50K
Gain or loss from assets sale	13.00K	13.00K	-	-

AI content may include mistakes. Learn more

Finance